Federico Cerrone, MD
Sleep Medicine · Summit, NJNPI 1184625220
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (51.5%), consulting fees and speaking fees — rather than concentrated in one kind of arrangement. Inspire Medical Systems, Inc. accounts for 60.1% of it on its own, with 31 other manufacturers making up the rest. Reporting peaked in 2024 at $7,501 and has fallen 88.8% since, to $842 in 2025. Among sleep medicine clinicians in NJ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 440 payments — averaging $30.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Inspire Medical Systems, Inc.$8K
- GSK$3K
- Boehringer Ingelheim$422
- Jazz Pharmaceuticals Inc.$294
- Resmed Corp$225
- Mylan Specialty L.p.$177
- plus $1K from 26 others
What the payments were for
- Consulting fees$2,96922%
- Speaking & faculty fees$2,00015%
- Travel & lodging$1,37610%
- Food & beverage$6,88551%
- Education$1441%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Inspire Medical Systems, Inc. | 36 | $8,041 |
| GSK | 260 | $2,866 |
| Boehringer Ingelheim | 28 | $422 |
| Jazz Pharmaceuticals Inc. | 15 | $294 |
| Resmed Corp | 3 | $225 |
| Mylan Specialty L.p. | 12 | $177 |
| Harmony Biosciences LLC | 8 | $149 |
| Regeneron Healthcare Solutions, Inc. | 10 | $142 |
| Sanofi | 8 | $125 |
| Insmed, Inc. | 8 | $122 |
| Amgen | 6 | $94 |
| Incyte Corporation | 5 | $86 |
| Pulmonx Corporation | 4 | $76 |
| Octapharma USA, Inc. | 3 | $64 |
| Grifols USA, LLC | 4 | $58 |
| Teva Pharmaceuticals USA, Inc. | 4 | $50 |
| Merck | 3 | $48 |
| Genentech USA, Inc. | 3 | $43 |
| Alk-abello, Inc | 3 | $39 |
| Mallinckrodt Enterprises LLC | 3 | $35 |
| Ambu Inc. | 1 | $28 |
| Kaleo, Inc. | 2 | $28 |
| AstraZeneca | 2 | $23 |
| Axsome Therapeutics, Inc. | 1 | $21 |
| Advanced Respiratory, Inc | 1 | $19 |
| Philips North America LLC | 1 | $17 |
| Optinose US, Inc. | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Circassia Inc. | 1 | $14 |
| Shire North American Group Inc | 1 | $13 |
| Eisai Inc. | 1 | $12 |
| Pharming Healthcare, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,374 in reported general payments places this provider in the 90th percentile of 40 sleep medicine providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XywavSodium,calcium,mag,pot Oxybate | 11 | $211,382 |
| Breo ElliptaFluticasone/Vilanterol | 33 | $23,387 |
| DuleraMometasone/Formoterol | 17 | $6,061 |
| QuviviqDaridorexant Hcl | 11 | $5,675 |
| Eszopiclone | 125 | $3,384 |
| Zolpidem Tartrate | 50 | $2,982 |
| Modafinil | 39 | $1,790 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 15 | $614 |
| Zaleplon | 22 | $539 |
| Zolpidem Tartrate ErZolpidem Tartrate | 28 | $415 |
| Alprazolam | 21 | $120 |
| Lorazepam | 16 | $44 |
| Clonazepam | 12 | $38 |
| Trazodone Hcl | 18 | $29 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKBreo Ellipta | $2,866 | $23,38733 claims |
| MerckDulera | $48 | $6,06117 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 40 sleep medicine providers in New Jersey.
Other sleep medicine in Summit
- Archana JayakumarSummit$2K
- William WeberSummit$746
- Jeffrey NahmiasSummit$451
- Prashant PatelBridgewater$20K
- Nehal MehtaBridgewater$19K
- Thanuja HamiltonMount Laurel$9K
- Jimmy HannaNewark$7K
- Tanuj BhatnagarJersey City$7K
- Bankim ShahBoonton$7K
- Kalpeshkumar PatelOld Bridge$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.